Adaptyx Biosciences, Inc.

Based in the US, Adaptyx Biosciences, Inc. develops innovative health monitoring solutions through advanced wearable technology that delivers continuous biochemical data essential for proactive healthcare management. Adaptyx Biosciences, Inc. specializes in wearable health technologies that enable continuous monitoring of critical biomarkers.

Founded in 2022 in Redwood City, US, the company has completed one funding round. In October 2025, Adaptyx raised USD 14. 00 mn in a Seed round led by INTERLAGOS CAPITAL, with other investors including Cantos Ventures, Humba Ventures, Hyperlink Ventures, Overwater Ventures, Seaside Ventures, Stanford University, and Starbloom Capital. The firm was founded by individuals with a background in biotechnology, yet specific details on their past ventures are not available.

Adaptyx's core offering is an advanced biochemical monitoring system encapsulated in a wearable patch designed to provide continuous health and biomarker intelligence. The platform transforms traditional lab-grade biochemical assays into a real-time data stream, enabling proactive healthcare management without the need for frequent clinic visits. The patch employs a minimally-invasive dermal probe to analyze interstitial fluid, allowing for the detection of key biomarkers such as hormones, glucose, and drug levels. Targeted use cases include managing chronic conditions like heart failure and chronic kidney disease, as well as monitoring hormone levels and facilitating precision pharmacology in clinical settings.

Adaptyx serves a diverse client base, including healthcare providers, hospitals, and patients, primarily across North America and Europe, with plans to expand into additional markets as demand for continuous health monitoring grows. Adaptyx generates revenue through a combination of direct-to-consumer and B2B business models, focusing on partnerships with healthcare institutions and providers. Clients engage with Adaptyx by integrating its wearable patch technology into their patient care protocols, thus facilitating continuous monitoring and data collection that enhances clinical decision-making. The company's revenue structure includes subscription-based services for ongoing access to its data analytics platform, as well as potential bulk purchasing arrangements for healthcare providers that utilize the patches in their practices.

The flagship product's value proposition centers on its ability to optimize treatment efficacy and improve diagnostic accuracy, driving demand among users who prioritize proactive health management solutions. In October 2025, Adaptyx Biosciences, Inc. raised USD 14 mn in Seed funding, led by INTERLAGOS CAPITAL, to expedite research and development efforts. The funds will be utilized to accelerate product development and add more molecular sensors, as well as support clinical trials for its wearable platform.

Adaptyx aims to launch new product iterations targeting enhanced monitoring capabilities within the next two years, with plans to expand its market presence into Asia and South America by 2026.